Aprea Therapeutics (APRE) Income from Continuing Operations (2022 - 2026)
Aprea Therapeutics (APRE) posted quarterly Income from Continuing Operations of 3430412.0 for Q1 2026, up 16.04% year-over-year from 2956330.46 in Q1 2025, and up 94.18% quarter-over-quarter from 58992372.0 in Q4 2025.
Aprea Therapeutics (APRE) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Income from Continuing Operations for 5 consecutive years, with 3430412.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 16.04% year-over-year to 3430412.0; the TTM figure through Mar 2026 stood at 68927945.0 (down 5.36% YoY), while the FY2025 annual figure was 69583115.0, down 7.91% from the prior year.
- Income from Continuing Operations climbed to 3430412.0 in Q1 2026 per APRE's latest filing, from 58992372.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2783600.0 in Q4 2022 and bottomed at 98529588.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 19244588.56 across 5 years, with a median of 3966253.0 in 2024.
- On a YoY basis, Income from Continuing Operations climbed as much as 96.29% in 2023 and fell as far as 1808.28% in 2023.
- Aprea Therapeutics' Income from Continuing Operations stood at 2783600.0 in 2022, then sank by 1808.28% to 53118788.0 in 2023, then dropped by 0.51% to 53391577.0 in 2024, then slipped by 10.49% to 58992372.0 in 2025, then surged by 94.18% to 3430412.0 in 2026.
- Business Quant data shows APRE's Income from Continuing Operations at 3430412.0 in Q1 2026, 58992372.0 in Q4 2025, and 3117388.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - | -3.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.03 Mn |
| Mar 31, 2026 | -3.43 Mn |
| Dec 31, 2025 | -58.99 Mn |
| Sep 30, 2025 | -3.12 Mn |
| Jun 30, 2025 | -3.39 Mn |
| Mar 31, 2025 | -4.09 Mn |
| Dec 31, 2024 | -53.39 Mn |
| Sep 30, 2024 | -4.10 Mn |
| Jun 30, 2024 | -3.85 Mn |
| Mar 31, 2024 | -3.15 Mn |
| Dec 31, 2023 | -53.12 Mn |
| Sep 30, 2023 | -3.52 Mn |
| Jun 30, 2023 | -3.65 Mn |
| Mar 31, 2023 | -4.62 Mn |
| Dec 31, 2022 | -2.78 Mn |
| Sep 30, 2022 | -4.19 Mn |
| Jun 30, 2022 | -98.53 Mn |